Alvotech Shares Surge as FDA Accepts AVT16 Biosimilar Application for Priority Review

The Quick Take

• FDA accepted Alvotech's BLA for AVT16 (ustekinumab biosimilar) and granted Priority Review, cutting the review timeline by six months
• Priority Review sets a 6-month PDUFA target date vs the standard 12 months, materially accelerating Alvotech's US market entry timeline
• Alvotech (ALVO) shares surged as AVT16 targets Stelara's US market, where ustekinumab generated over $10 billion in peak annual global revenue

Alvotech (ALVO) received a significant regulatory milestone as the US Food and Drug Administration accepted its Biologics License Application for AVT16, the company's proposed biosimilar to Stelara (ustekinumab), and granted the filing Priority Review status. Priority Review designation accelerates the FDA's target action date from the standard twelve months to approximately six months from filing acceptance, meaningfully compressing Alvotech's timeline to potential US market entry in the immunology biosimilar space.

The commercial significance of the FDA's acceptance is amplified by ustekinumab's market profile. Stelara, manufactured by Johnson & Johnson, generated peak annual global revenues exceeding $10 billion, with the US market representing the dominant share. As Stelara's US patent exclusivity period concludes, biosimilar entrants stand to capture substantial market share by offering equivalent clinical efficacy at meaningfully lower price points—a dynamic that has played out in prior large-molecule biosimilar markets. AVT16's Priority Review status positions Alvotech to potentially be among the first-to-file entrants in this lucrative segment.

For investors, the FDA filing acceptance removes a key early-stage regulatory uncertainty and validates Alvotech's manufacturing and clinical dossier quality. The company's shares responded positively as the market repriced the probability-weighted commercial value of AVT16. Analysts will now focus on the PDUFA date and any FDA advisory committee proceedings, while monitoring whether Johnson & Johnson pursues patent challenge litigation that could delay commercial launch even after FDA approval. Alvotech's ability to execute on its biosimilar pipeline makes AVT16 a critical program for demonstrating commercial viability.

Synthesized from 2 sources.